Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


Our top-notch dedicated system is used to design specialised libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
Q9BZ23

UPID:
PANK2_HUMAN

ALTERNATIVE NAMES:
Pantothenic acid kinase 2

ALTERNATIVE UPACC:
Q9BZ23; B1AK33; B2Z3X0; D3DVZ0; Q5T7I2; Q5T7I4; Q7RTX5; Q8N7Q4; Q8TCR5; Q9BYW5; Q9HAF2

BACKGROUND:
Pantothenate kinase 2 is crucial for CoA synthesis, impacting energy metabolism and lipid synthesis. Its mitochondrial and cytoplasmic isoforms underscore its importance in cellular energy homeostasis. The enzyme's role in angiogenesis further highlights its potential in tissue repair and regeneration.

THERAPEUTIC SIGNIFICANCE:
Linked to diseases such as Neurodegeneration with brain iron accumulation 1 and Hypoprebetalipoproteinemia, Pantothenate kinase 2 represents a significant target for therapeutic intervention. Its involvement in these diseases suggests that modulating its activity could offer new avenues for treatment.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.